Evidence map›Paper›PMID 31808008›Full record

ArticleEndocrine pathology2020

Prognostic Impact of MCPyV and TIL Subtyping in Merkel Cell Carcinoma: Evidence from a Large European Cohort of 95 Patients.

C Ricci, A Righi, F Ambrosi, D Gibertoni, F Maletta, S Uccella, F Sessa, S Asioli, M Pellilli, R Maragliano and 3 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Endocrine pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

C RicciDepartment of Biomedical and Neuromotor Sciences, Section of Anatomic Pathology "M. Malpighi", Bellaria Hospital, 40139, Bologna, Italy.
A RighiDepartment of Pathology, Rizzoli Institute, 40136, Bologna, Italy.
F AmbrosiDepartment of Biomedical and Neuromotor Sciences, Section of Anatomic Pathology "M. Malpighi", Bellaria Hospital, 40139, Bologna, Italy.
D GibertoniDepartment of Biomedical and Neuromotor Sciences, Unit of Hygiene and Biostatistics, University of Bologna, 40126, Bologna, Italy.
F MalettaDepartment of Oncology, University of Turin at Città della Salute Hospital, 10124, Turin, Italy.
S UccellaUnit of Pathology, Department of Medicine and Surgery, University of Insubria, 21100, Varese, Italy.
F SessaUnit of Pathology, Department of Medicine and Surgery, University of Insubria, 21100, Varese, Italy.
S AsioliDepartment of Pathology, Morgagni-Pierantoni Hospital, 47121, Forlì, Italy.
M PellilliUnit of Pathology, Department of Medicine and Surgery, University of Insubria, 21100, Varese, Italy.
R MaraglianoUnit of Pathology, Department of Medicine and Surgery, University of Insubria, 21100, Varese, Italy.
S La RosaService of Clinical Pathology, Institute of Pathology, Lausanne University Hospital and University of Lausanne, CH-1011, Lausanne, Switzerland.
M G PapottiDepartment of Oncology, University of Turin at Città della Salute Hospital, 10124, Turin, Italy.
S AsioliDepartment of Biomedical and Neuromotor Sciences, Section of Anatomic Pathology "M. Malpighi", Bellaria Hospital, 40139, Bologna, Italy. sofia.asioli3@unibo.it.
University of Insubria · ITOspedale Bellaria · ITOspedale G.B. Morgagni - L.Pierantoni · ITUniversity of Turin · ITIstituto Ortopedico Rizzoli · ITUniversity of Bologna · ITUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Merkel cell carcinoma is a rare (∼ 2000 cases/year in the USA) but aggressive neuroendocrine neoplasm of the skin. In 2008, the Merkel cell polyomavirus (MCPyV) was found to be clonally integrated in approximately 80% of Merkel cell carcinomas. The remaining 20% have large numbers of UV-associated mutations. Importantly, both the UV-induced neoantigens in virus-negative Merkel cell carcinoma and the Merkel cell polyomavirus oncogenes that are required for virus-positive tumor growth are highly immunogenic. Indeed, antigen-specific T cells detected in patients are frequently "dysfunctional/exhausted," and the inhibitory ligand PD-L1 is often expressed by Merkel cell carcinoma cells. These data led to point our attention on the quantity and the quality of the immune response in Merkel cell carcinoma. Here, we found CD8+ lymphocytes are the only singly evaluated lymphocyte subclass that strongly influenced overall survival and disease-specific survival in Merkel cell carcinoma. In addition, we highlighted as Merkel cell polyomavirus is a strong prognostic factor and as it prompts a host immune response involving various lymphocyte subclasses (CD3, CD8, FoxP3, and PD-L1 positive) in MCC. For this reason, we proposed a novel eye-based "immunoscore" model, obtained by tumor infiltrating lymphocytes subtyping (CD3, CD8, FoxP3, and PD-L1) that could provide additional prognostic information in Merkel cell carcinoma.

Indexed as

AgedAged, 80 and overCarcinoma, Merkel CellCD8-Positive T-LymphocytesCohort StudiesEuropeFemaleHumansKaplan-Meier EstimateLymphocytes, Tumor-InfiltratingMaleMerkel cell polyomavirusMiddle AgedPolyomavirus InfectionsPrognosisRetrospective StudiesImmunoscore: Merkel cell carcinomaMerkel cell polyomavirusTumor-infiltrating lymphocytes (TILs)

Identifiers

PMID31808008
OpenAlexW2994380541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.